ERC Consolidator Grant · 2023
Repair mechanisms of topoisomerase II DNA lesions
Topoisomerase II (TOP2) chemotherapeutics such as etoposide have been widely used in the clinic to treat leukemias, lymphomas, lung, testicular, and ovarian cancers. Etoposide was first approved for clinical usage in 1983. By intercalating into DNA, etoposide stalls the TOP2 catalytic cycle, generating toxic DNA lesions known as TOP2-DNA-protein crosslinks (TOP2-DPCs). After 40 years of intense research, the mechanisms employed by cells that counteract these lesions are starting to emerge. These include enzymes that reverse the crosslink, degrade the protein adduct, or remove the lesion by DNA incisions. Moreover, the protein ZATT was recently described as an essential regulatory enzyme…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.